7 results
PRE 14A
ONCR
Oncorus, Inc.
12 Jun 23
Preliminary proxy
6:33am
, the we received written notice from Nasdaq that, in light of the Plan of Dissolution, the Workforce Reduction Plan and based upon Nasdaq’s review … that the Board had approved a plan to reduce our workforce by 55 employees, representing substantially all of our headcount, in order to preserve cash
8-K
ONCR
Oncorus, Inc.
9 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:26pm
, 2023, that the Board had approved a workforce reduction plan (the "Workforce Reduction Plan") impacting substantially all of the Company's remaining … ("Nasdaq") that, in light of the Plan of Dissolution, the Workforce Reduction Plan and based upon Nasdaq’s review of the Company and pursuant to Nasdaq
8-K
EX-99.1
ONCR
Oncorus, Inc.
1 Jun 23
Oncorus Announces Workforce Reduction Plan
4:34pm
Exhibit 99.1
Oncorus Announces Workforce Reduction Plan
Andover, Mass., June 1, 2023 – Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company … , the Company’s board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus
8-K
EX-99.1
ONCR
Oncorus, Inc.
22 May 23
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
4:13pm
product candidates manufactured in accordance with regulatory requirements; Oncorus’ ability to hire and retain its workforce suitable to meet its business
8-K
EX-99.1
qafy mdzda
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
8-K
1kkkprgjf9
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
- Prev
- 1
- Next